• Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Home
  • About
  • Consumer Info
  • Guideline Notes
  • Medicine and Media
  • Pharmacogenomics
  • Visit My Etsy Store

Digital PharmD

Informatics in Pharmacy

Hepatitis

August 12, 2018 By Dr. G, PharmD

Print Friendly, PDF & Email

Hepatitis A – viral – spread person to person via feces.

Pre-exposure prophylaxis

  • Vaccines are available.
    • Children are routinely vaccinated between their first and second birthdays.
    • People who should consider vaccine –
      • are traveling to countries where hepatitis A is common,
      • are a man who has sex with other men
      • use illegal drugs,
      • have a chronic liver disease such as hepatitis B or hepatitis C,
      • are being treated with clotting-factor concentrates,
      • work with hepatitis A-infected animals or in a hepatitis A research laboratory
      • have occupational risks (sewer workers, food handlers)
      • expect to have close personal contact with an international adoptee from a country where hepatitis A is common
  • Immune fab (IG) also available
    • Pre-exposure prophylaxis with the immune fab is only recommended in children less than 1-year-old or travelers who don’t have four weeks for full protection from vaccine.
  • Post-exposure prophylaxis
    • HepA vaccine or IG should be administered within 14 days to all previously unvaccinated persons who have been exposed or are at risk of exposure due to close personal contacts of persons with serologically confirmed hepatitis A (i.e., through a blood test), including:
      • household and sex contacts and
      • persons who have shared injection drugs with someone with hepatitis A
      • caretakers not using appropriate personal protective equipment
      • Consideration should also be given to providing IG or hepatitis A vaccine to persons with other types of ongoing, close personal contact with a person with hepatitis A (e.g., a regular babysitter or caretaker).
    • Can get the immune globin if 12 months to 40 years old and it is within 2 weeks of exposure.
    • If a food handler receives a diagnosis of hepatitis A, post-exposure prophylaxis should be administered to other food handlers at the same establishment and identfied patrons during the time the food handler was symptomatic and worked, though transmission to patrons is rare.

Hepatitis B – viral HBV, passed in bodily fluids (blood, semen, saliva, vaginal fluids)

  • Vaccine available, recommended for:
    • Newborns
    • Children and adolescents not vaccinated at birth
    • Those who work or live in a center for people who are developmentally disabled
    • People who live with someone who has hepatitis B
    • Health care workers, emergency workers and other people who come into contact with blood
    • Anyone who has a sexually transmitted infection, including HIV
    • Men who have sex with men
    • People who have multiple sexual partners
    • Sexual partners of someone who has hepatitis B
    • People who inject illegal drugs or share needles and syringes
    • People with chronic liver disease
    • People with end-stage kidney disease
    • Travelers planning to go to an area of the world with a high hepatitis B infection rate
  • Post-exposure
    • Interferon
    • Reverse transcriptase inhibitors (lamivudine, adefovir, entecavir, telbivudine, tenofovir)\
    • Can give immune globin up to 7 days after exposure

Hepatitis C – mostly blood born

  • Ribavirin, protease inhibitors (simeprevir), polymerase inhibitors (sofosbuvir)
  • First two weeks of therapy can cause hemolysis, sclerel icterus, rapid decline in hematocrit, fatigue and elevated indirect bilirubin (hemolytic anemia) from ribavirin.

Alcoholic hepatitis

  • Maddrey Discriminant Function (MDF) = 4.6 (pt PT – control PT) + total bilirubin
  • >32 is poor prognosis.  Can do 4-week steroid and taper in this case.

Filed Under: Gastrointestinal

Primary Sidebar

Newsletter

More to See

What You Need to Know About the 2022 Avian Influenza Outbreak

March 20, 2022 By Dr. G, PharmD

Endocarditis Guideline Review

February 24, 2022 By Dr. G, PharmD

Sinus Troubles: When Should I See My Doctor

January 5, 2022 By Dr. G, PharmD

Tags

acid base acidosis acute coronary syndrome alkalosis analgesics anaphylaxis aortic dissection arrhythmia Beta-Blockers biostatistics blood pressure cardiac markers CHA2DS2-VasC cocaine COVID-19 diabetes diabetes inspidius Guidelines heart failure Heparin hypersensitivity hypertension hypovolemic shock intubation ionotropes journal club lipids LMWH medication safety morphine conversions myocardial infarction needs work NOAC NSTEMI obstructive shock pharmacoeconomics pheochromocytoma pressors reference materials right mi sedation septic shock shock STEMI Updated 2020

Footer

Medical Disclaimer

The medical information on this website is provided “as is” without any representations or warranties, express or implied. GoPharmD makes no representations or warranties in relation to the medical information on this website.

GoPharmD does not warrant that:

  • the medical information on this website will be constantly available, or available at all; or
  • the medical information on this website is complete, true, accurate, up-to-date, or non-misleading.
  • You must not rely on the information on this website as an alternative to medical advice from your doctor or other professional healthcare provider.
  • If you have any specific questions about any medical matter you should consult your doctor or other professional healthcare provider.

Recent

  • Smoking
  • What You Need to Know About the 2022 Avian Influenza Outbreak
  • Endocarditis Guideline Review
  • Sinus Troubles: When Should I See My Doctor
  • Common Pharmacogenomic SNPs and Interactions

Search

Tags

acid base acidosis acute coronary syndrome alkalosis analgesics anaphylaxis aortic dissection arrhythmia Beta-Blockers biostatistics blood pressure cardiac markers CHA2DS2-VasC cocaine COVID-19 diabetes diabetes inspidius Guidelines heart failure Heparin hypersensitivity hypertension hypovolemic shock intubation ionotropes journal club lipids LMWH medication safety morphine conversions myocardial infarction needs work NOAC NSTEMI obstructive shock pharmacoeconomics pheochromocytoma pressors reference materials right mi sedation septic shock shock STEMI Updated 2020